Dose-Intense Temozolomide in Recurrent Glioblastoma

Model scores of the 29,894 trials active now.

Model score 34% for any early termination, 26% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: recurrenttumorcancertemozolomidecarcinoma
  Phrases that lowered it: participantparticipantsm2dayrelevant
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Collaborators: 7 (lowers risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports with a death: 24.0% (raises risk) · Drug's FDA history
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 93.5% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma NCT00941460 · started 2009 · scored riskier than 87% of active trials completed
• A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse NCT02330991 · started 2015 · scored riskier than 89% of active trials completed
• Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. NCT02209948 · started 2014 · scored riskier than 88% of active trials completed
• Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415 · started 2018 · scored riskier than 94% of active trials completed
• TPI 287 in Patients With Recurrent Glioblastoma Multiforme NCT01113463 · started 2010 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.